Marrone Bio Innovations, Inc. (MBII) financial statements (2021 and earlier)

Company profile

Business Address 1540 DREW AVENUE
DAVIS, CA 95618
State of Incorp. DE
Fiscal Year End December 31
SIC 287 - Agricultural Chemicals (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments68914182123
Cash and cash equivalents68914182123
Restricted cash and investments     00
Receivables6779335
Inventory, net of allowances, customer advances and progress billings8988899
Inventory8988899
Other undisclosed current assets1211111
Total current assets:22262731303438
Noncurrent Assets
Operating lease, right-of-use asset5555
Property, plant and equipment13131414151515
Intangible assets, net (including goodwill)3132     
Goodwill77     
Intangible assets, net (excluding goodwill)2424     
Restricted cash and investments2222222
Other noncurrent assets1110000
Total noncurrent assets:51522121161717
TOTAL ASSETS:73784752475155
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1617129987
Accounts payable3222221
Accrued liabilities1215107766
Deferred revenue0000
Debt4746223
Other undisclosed current liabilities1111000
Total current liabilities:21251716111010
Noncurrent Liabilities
Long-term debt and lease obligation16161616121212
Long-term debt, excluding current maturities12121212121212
Operating lease, liability4445
Liabilities, other than long-term debt12131010888
Deferred revenue2222
Due to related parties7777777
Other liabilities3411111
Other undisclosed noncurrent liabilities    233
Total noncurrent liabilities:28292627222323
Total liabilities:49544443343233
Stockholders' equity
Stockholders' equity attributable to parent2425310131822
Common stock0000000
Additional paid in capital344335298297296294293
Accumulated deficit(321)(311)(294)(287)(283)(275)(271)
Total stockholders' equity:2425310131822
TOTAL LIABILITIES AND EQUITY:73784752475155

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Revenues7779656
Cost of revenue(3)(3)(3)(4)(3)(3)(3)
Gross profit:4445333
Operating expenses(12)(13)(10)(9)(8)(7)(7)
Operating loss:(8)(10)(6)(4)(5)(4)(4)
Nonoperating expense(2)(7)(0)(0)(3)(0)(0)
Interest and debt expense(0)(0)(0)(0)(2)(0)(0)
Other undisclosed income from continuing operations before equity method investments, income taxes1      
Loss from continuing operations before income taxes:(9)(17)(7)(4)(10)(5)(5)
Other undisclosed loss from continuing operations(0)      
Net loss:(9)(17)(7)(4)(10)(5)(5)
Other undisclosed net income (loss) attributable to parent(1)000200
Net loss available to common stockholders, diluted:(10)(16)(7)(4)(8)(4)(5)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(9)(17)(7)(4)(10)(5)(5)
Comprehensive loss, net of tax, attributable to parent:(9)(17)(7)(4)(10)(5)(5)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: